In the News
Russo Partners works at the intersection of science, medicine, and media. The stories below reflect the conversations we help shape covering breakthroughs in biopharma, digital health, healthcare, and beyond.
Time
|
October 15, 2026
Syndax Revuforj
For decades, patients with some of the most aggressive forms of leukemia had few targeted treatment options. Now, Revuforj is…
For more
Citeline In Vivo
|
October 13, 2026
Ex-FDA Chief Woodcock: Spinal Cord Injury Drugs Need Different Trials
Spinal cord injury needs rare-disease-style flexibility, said Janet Woodcock in an interview. Randomized trials require prespecified, individualized responder indices and…
For more
Healio
|
October 12, 2026
Single rademikibart dose reduces COPD exacerbation-related ED, hospital readmissions
Among patients with COPD and type 2 inflammation at an urgent outpatient visit, the ED or hospital, a single dose…
For more
Parkinson’s News Today
|
October 6, 2026
Use of newly named drug leads to stable motor symptoms in Parkinson’s
Gain Therapeutics’ oral therapy candidate rexaceract, formerly called GT-02287, stabilized motor symptoms in a small group of people with Parkinson’s…
For more
Becker Business Podcast
|
October 1, 2026
Biotech Growth, Capital, and M&A with Dr. Howard Berman of ReAlta Life Sciences
In this episode, Howard Berman, Ph.D., CEO of ReAlta Life Sciences, discusses biotech growth strategy, capital planning, M&A, drug development…
For more
Citeline In Vivo
|
September 28, 2026
Strategic Intent: Boehringer Ingelheim’s Brian Hilberdink on Launching Into the GLP-1 Era
Boehringer Ingelheim’s US Human Pharma president on navigating a major launch cycle, competing in obesity without chasing pounds, and playing…
For more
San Diego Business Journal
|
September 24, 2026
Persephone Bio Synbiotic Giving Good Gut Feeling
Roughly 90% of babies in the U.S. are born without the essential levels of certain gut bacteria that they need…
For more
FOX10
|
September 17, 2026
Arizona researchers pioneer autism urine screening targeting gut bacteria
A breakthrough in autism research in the Valley is offering incredible new hope to families. A Phoenix-based company is looking…
For more
Biotech TV
|
September 15, 2026
HCW 2026: InflaRx designed izicopan from the start with the goal of having a differentiated, best in class profile vs the first marketed C5aR inhibitor. Now more than ever this could be opportune
Founder & CEO Niels Riedemann describes what he believes was lacking in design for the competitor, avacopan, which has been…
For more
PharmaVoice
|
September 15, 2026
Cocrystal Pharma’s new CEO hopes to crack the norovirus code
James Sapirstein is bringing his Big Pharma chops to the clinical-stage company’s efforts to finally deliver an effective treatment for…
For more
Upcoming Events
Our team is active across the industry year-round. Find us at these upcoming conferences and events.
